Successful management of imatinib despite alopecia and nail necrosis
No Thumbnail Available
Date
2013
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Imatinib mesylate selectively inhibits bcr/abl and other non-specific tyrosine kinases, such as c-kit and platelet derived growth factor (PDGF) receptor and successfully used to treat chronic myeloid leukaemia (CML). In most cases, the drug is well tolerated: however, side effects can be seen. Hair loss and paronychia inflammation were often reported with Imatinib, but total alopecia was rarely mentioned. We report a CML patient who was presented with alopecia and paronychia inflammation probably induced by imatinib therapy. We have successfully treated our patient by cessation and then re-applying therapy with lower doses after improvement of lesions and have not found a similar report in literature. © 2013 Elsevier Ltd.
Description
Keywords
Alopecia , Benzamides , Humans , Leukemia, Myelogenous, Chronic, BCR-ABL Positive , Male , Middle Aged , Necrosis , Paronychia , Piperazines , Pyrimidines , imatinib , mometasone furoate , steroid , adult , alopecia , article , cancer chemotherapy , case report , chronic myeloid leukemia , corticosteroid therapy , diarrhea , drug eruption , drug withdrawal , eosinophilia , human , human tissue , male , nail disease , nail necrosis , nephrectomy , orbit edema , poliomyelitis , skin biopsy , skin necrosis , steroid therapy